Close this search box.

Limited Distribution Updates

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the early press releases rarely specify the specialty pharmacy(ies) selected as the designated partner(s).

Here are four LD deals that have been publicly confirmed subsequent to their approvals.

ONCO360 to distribute Voydea

Onco360 has been selected as a national pharmacy partner by Alexion Pharmaceuticals for Voydeya (danicopan) as a first class oral, Factor D inhibitor for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in combination with C5 inhibitor, Ultomiris (ravulizumab) or Soliris (eculizumab) for patients that experience clinically significant extravascular hemolysis (EVH).1 Voydeya® is an oral, Factor D inhibitor that acts in the alternative complement pathway of the immune system, providing control of red blood cell destruction within and outside the blood vessels.

ONCO360 to distribute Ojemda

Onco360 has been selected as a pharmacy partner by Day One Biopharmaceuticals for Ojemda (tovorafenib), which is now FDA approved for the treatment of patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

Orsini Specialty Pharmacy to Dispense Yargesa

Orsini Specialty Pharmacy has been selected by Edenbridge Pharmaceuticals as the preferred specialty pharmacy partner for the distribution of Yargesa (miglustat) capsules, 100mg. YARGESA is a glucosylceramide synthase inhibitor indicated for the treatment of adult patients with Type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.

PANTHERx Rare to distribute Yargesa

PANTHERx Rare announced that it was selected by Edenbridge Pharmaceuticals for the distribution of Yargesa (miglustat) capsules, the first oral treatment option for adults with mild to moderate Type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.


Read More

CGT Driving New Programs at WAGS

Our last few Reports focused on approvals and developments in the Cell and Gene Therapy (CGT) categories. A recent press release from a major national pharmacy


CGT…… What’s in Your Future?

Today we are pleased to offer a review of an article from which just about anyone working in the specialty pharmacy segment might learn something…. or

Send Us A Message

This website uses cookies to ensure you get the best experience on our website.